Sinovac's COVID-19 vaccine induces quick antibody responses: study



The experimental COVID-19 vaccine developed by China's Sinovac Biotech can induce quick antibody responses and is suitable for emergency use, preliminary trial results published in the medical journal The Lancet Infectious Diseases showed on Wednesday.

CoronaVac, Sinavac's vaccine, "was well tolerated and induced humoral responses against SARS-CoV-2, which supported the approval of emergency use of CoronaVac in China and in three phase 3 studies," the findings read.